FarmaBios successfully completed the certification process in accordance with the ISO 45001:2018 standards. The new certificate is the last achievement of the list together with ISO 9001:2015 and ISO 14001:2015. With this certificate valid until 28th July 2023, FarmaBios presents objective evidence for the commitment to provide high quality and to works on continuous improvement
PharmaZell Group is very conscious of our important role and duty in delivering APIs to our customers and being an active part in maintaining the health system running. Up to now, the PharmaZell Group has been able to limit the impact of the Corona Virus outbreak (COVID-19) to the largest extent. Despite the fact that
As part of an ongoing investment program to enhance PharmaZell Group’s production output, we have initiated the construction of a brand new large steroid building and a new warehouse on the Farmabios premises in Gropello Cairoli (Italy). Construction work began in Dec 2019, a symbolic ground breaking ceremony is planned for Mar 2020. The investment
We are very glad to announce that the competent Italian authority (AIFA) has issued a renewed GMP certificate for our Farmabios SpA production facility [http://eudragmdp.ema.europa.eu/inspections/gmpc/generateGMPCPDF.do].
Global API supplier Farmabios announced today the addition of an ultra-pure synthetic Cannabidiol (CBD) drug substance to its portfolio. With an EU Drug Master File and cGMP manufacturing capacities, Farmabios is now positioned to fulfill a secure and scalable supply of CBD, from clinical needs to full-scale commercial operations. “As a long-standing supplier of specialized